Skip to main content
  • Addex Announces Corporate Reorganization and Restructuring Initiative to Strengthen Its Leadership Position in Allosteric Modulation-Based Drug Discovery and Development

    July 7, 2011

Focus on Core R&D Programs
Goals Include: Increased Operational Efficiency, Strategic Partnerships with Industry Leaders

Geneva, Switzerland, 7 July 2011 – Allosteric modulation company Addex Pharmaceuticals Ltd (SIX:ADXN) announced today that it is planning organizational changes to strengthen its leadership position in the field of allosteric modulation-based drug discovery and development and continue to deliver shareholder value from a robust clinical and preclinical pipeline. Addex will continue to position itself as a partner of choice for discovery and development of allosteric modulators with leading large pharmaceutical and biotechnology companies while building and advancing a robust pipeline of high-value therapeutic programs.

Following a careful review of Addex operations, the Board of Directors has decided that, in order to ensure the continued development of a robust pipeline through efficient use of its strong balance sheet and capital resources, Addex will strategically focus on changes that prioritize strong management, timely decision-making and efficient use of resources. The company will continue to focus on research and development in its core therapeutic areas – central nervous system, metabolism and inflammation – and maintain its core competencies, including those in preclinical and clinical development.

The company plans to pursue new strategic partnerships with industry leaders on mGluRs, GLP-1 receptor, TNF receptor superfamily, interleukin receptor family and receptor tyrosine kinase superfamily. The three existing drug discovery and development partnerships are currently fully funded by Ortho-McNeil-Janssen Pharmaceuticals Inc. and Merck & Co., Inc., which have assumed full responsibility for further development following successful discovery collaborations. Addex will use its platform technologies for drug discovery and development to continue to build a robust pipeline as well as pursue collaborations on targets specified by potential partners.

As part of the restructuring, the Addex Group’s headcount is expected to be reduced by about 25%. To this end, a consultation process, required under Swiss law, has been initiated for the employees of the Swiss entity. During the consultation period, the management will work to determine the specific details of the restructuring. An announcement detailing the new organization and the resulting cost savings will be made thereafter.

“The loss of people’s jobs at Addex is something the Board regrets,” said André Mueller, executive chairman of Addex. “However, the future of the company is now more secure. We believe Addex is a world class research and development organization capable of delivering on the promise of this exciting technology.”

“Our objective is to realize annual savings of approximately CHF8 million, through improved operational effectiveness, extending the cash reach of the company through end of 2013 and providing a stronger financial base for future success” said Tim Dyer, CFO.

Addex is making excellent progress developing its proprietary pipeline. Two Phase IIa clinical trials are ongoing for two lead products: dipraglurant (ADX48621) and ADX71149. Dipraglurant is an mGluR5 negative allosteric modulator (NAM), which is being tested in Parkinson’s disease levodopa-induced dyskinesia (PD-LID). ADX71149, an mGluR2 positive allosteric modulator (PAM), is being tested for treatment of schizophrenia by partner Ortho-McNeil-Janssen Pharmaceuticals Inc. In addition, Merck & Co., Inc., has licensed rights to two preclinical programs: mGluR4 PAM for Parkinson’s disease and mGluR5 PAM for schizophrenia. Unpartnered preclinical programs available for out-licensing include: follicle stimulating hormone receptor (FSHR) NAM, with potential for endometriosis and benign prostatic hyperplasia; mGluR2 NAM for Alzheimer’s disease; and GABA-BR PAM with potential for chronic pain, Fragile X syndrome, urinary incontinence and gastroesophageal reflux disease; and TrkB PAM for neurodegenerative disorders. Preclinical diabetes and inflammation discovery programs include GLP-1R PAM, IL-1R1 NAM, and TNFR1 NAM.